Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer
about
Update on advances in molecular PET in urological oncologyIncreased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapyFDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.Metabolic reprogramming in clear cell renal cell carcinoma.Downregulation of WDR20 due to loss of 14q is involved in the malignant transformation of clear cell renal cell carcinoma.Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers.Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer.PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.Clinically significant association of elevated expression of nuclear factor E2-related factor 2 expression with higher glucose uptake and progression of upper urinary tract cancer.Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of PET-CT.Increased Nrf2 expression by renal cell carcinoma is associated with postoperative chronic kidney disease and an unfavorable prognosis.
P2860
Q33625389-BE88CA24-A62E-4C05-8567-16944228BDA6Q33730033-574BEF8A-D321-4FDB-869C-D1BDC83D372AQ35917780-C458A69E-2CF8-4318-ACCC-45045C9D3B3AQ39290307-1B165AD1-05D9-47DE-8136-93F0EE9E68E7Q40083285-B64EB03D-2AB1-43E1-8371-C70AEB038386Q41491212-B5A342EB-FE54-4148-8AC4-0840D4171285Q41660750-1C56D6CA-9686-4796-BB38-44EBEC24687FQ47855049-C0CEE592-D9E5-4368-B78E-EF65533E5F22Q49165684-89580196-0C40-412F-88FB-41EF92729447Q52780316-9A4ADEAA-54C0-4497-8D06-4FB71622E8D7Q54969502-10C26131-783F-469B-BBEA-B2F38DFD22E4Q55282579-AB596720-F7AA-407A-AB25-A5A9196DA093Q55446037-33EA59F5-BCD2-4981-8074-FB62A61BC416
P2860
Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Clinically significant associa ...... teristics of renal cell cancer
@ast
Clinically significant associa ...... teristics of renal cell cancer
@en
type
label
Clinically significant associa ...... teristics of renal cell cancer
@ast
Clinically significant associa ...... teristics of renal cell cancer
@en
prefLabel
Clinically significant associa ...... teristics of renal cell cancer
@ast
Clinically significant associa ...... teristics of renal cell cancer
@en
P2093
P2860
P1433
P1476
Clinically significant associa ...... teristics of renal cell cancer
@en
P2093
Daisaku Nishihara
Hideo Yuki
Hideyuki Abe
Hironori Betsunoh
Kazuhiro Kitajima
Ken-Ichiro Yoshida
Masahiro Yashi
Setsu Sakamoto
Takao Kamai
Tomoya Mizuno
P2860
P2888
P356
10.1186/S12885-015-1097-0
P407
P577
2015-03-10T00:00:00Z
P5875
P6179
1038021994